Quanterix

The company posted Q4 revenues of $26.1 million, up from $15.9 million in Q4 2019, and beat the consensus Wall Street estimate of $23.4 million.

News items for the in vitro diagnostics industry for the week of Feb. 8, 2021.

The company said it has priced a public offering of 3,571,428 shares of its common stock at $70.00 per share.

The company also projected full year 2020 revenue of between $84 million and 86 million and said that its instrument install base grew 34 percent over the year.

The company's automated immunoassay is designed to qualitatively detect the SARS-CoV-2 nucleocapsid protein antigen in nasopharyngeal swab specimens.

The EUA for the antibody test follows funding that Quanterix received recently from BARDA for the development of a SARS-CoV-2 antigen test.

For the three months ended Sept. 30, the Billerica, Massachusetts-based company posted Q3 revenues of $31.4 million, up from $14.9 million in Q3 2019.

The awards will support clinical validation, manufacturing, and scale up for SARS-CoV-2 viral antigen and molecular detection.